Description
EORTC has a strong track record in initiating and conducting clinical trials across thoracic cancers. The focus is not only lung cancer but also mesothelioma and thymomas. This follows EORTC strategy to challenge, re-define and develop standards of care for loco-regional as well as for systemic treatments.
Scientific projects are designed and conducted to integrate disciplines such as imaging, translational research, quality of life and quality assurance. There are multiple partnerships, especially with national groups in Europe but also with international umbrella organisations. The group places special emphasis on recruiting and mentoring junior colleagues who are interested in pursuing an academic career in the field of thoracic oncology.
Projects testing the place of immunotherapy in the treatment of lung cancer are also ongoing such as addressing the role of immunotherapy in the adjuvant setting of lung cancer.
Recruiting Clinical Trials
All clinical trials in this research field-
Phase 2-3
Targeted therapy with or without dose intensified radiotherapy for oligo-progressive disease in oncogene-addicted lung tumours
-
Phase 2
Activity of Lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with 2nd generation ALK inhibitor
-
Phase 3
PRophylactic cerebral Irradiation or active MAgnetic resonance imaging surveillance in small-cell Lung cancer patients (PRIMALung study)
Main Achievements
EORTC has contributed to changing the standards of care for thoracic oncology:
Established radiotherapy as the preferred loco-regional treatment in non-small-cell lung cancer patients. (More information & More information)
Demonstrated the benefit of prophylactic cranial irradiation to reduce the incidence of symptomatic brain metastases in extensive small-cell lung cancer. More information
Confirmed a combination of Cisplatin and Raltitrexed was more effective than Cisplatin alone in improving the survival of patients with Malignant Pleural Mesothelioma (MPM). More information
Related Projects
- 1459: Exploratory analysis of the pleural mesothelioma genome by next generation sequencing
- 1495: Update of OS in 08092 and CRP marker
- 1496: Survey on Thymoma / thymic malignancy
- 1492 CANCER-ID: Cancer treatment and monitoring through identification of circulating tumor cells and tumor related nucleic acids in plasma
- 1549: Pharmacogenetic analysis from the double blind randomized phase III study ofmaintenance pazopanib versus placebo in NSCLC patients non progressive after first line chemotherapy. MAPPING, an EORTC Lung Group study
- 1557 Predict therapy in NSCLC: Studying changes in the expression of genes related to the metabolism and the chemotherapeutic activity in primary tumor and lymph and mediastinal lymph nodes infiltrated in resectable NSCLC
- 1638: Phase II, Parallel-Arm Study of MGCD265 in patients with locally advanced or metastatic NSCLC with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor
Research Group
Group documents-
Chair
Benjamin Besse
Gustave Roussy Cancer Campus
Villejuif, France
-
Secretary
Silvia Novello
Ospedale S. Luigi Gonzaga - Universita Di Torino
Orbassano, Italy
-
Treasurer
Thierry Berghmans
Institut Jules Bordet
Brussels, Belgium
Other members
-
C. Faivre-Finn - Manchester, GB
Early stage NSCLC & Radiotherapy
The Christie NHS Foundation Trust
-
M. De Waele - Edegem, BE
Early stage NSCLC & Surgery
Universitair Ziekenhuis Antwerpen
-
M. Reck - Grosshansdorf, DE
Metastatic NSCLC
Hospital Grosshansdorf
-
L. Greillier - Marseille, FR
Malignant Pleural Mesothelioma
Assistance Publique - Hopitaux de Marseille - Hopital Nord
-
S. Lantuejoul - Grenoble, FR
Pathology & TR
CHU de Grenoble - Departement d'Anatomie et Cytologie Pathologiques
-
A. Dingemans - Maastricht, NL
SCLC
Academisch Ziekenhuis Maastricht
-
N. Girard - Lyon, FR
Thymic malignancies
CHU de Lyon - Hopital Louis Pradel